KNOMATIC
LIVE

Serial Number

98720113

Owner

Moma Therapeutics, Inc.

Attorney

Gregory B. Coy

First Use Date

Aug 19, 2024

Filing Date

Aug 27, 2024

Add to watchlist:

No watchlists yet
View on USPTO

KNOMATIC Trademark

Serial Number: 98720113

KNOMATIC is a trademark filed by Moma Therapeutics, Inc. on August 27, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Moma Therapeutics, Inc.

20 Acorn Park
Cambridge, MA 02140

Entity Type: 03

Trademark Details

Filing Date

August 27, 2024

Registration Date

Not Registered

First Use Anywhere

August 19, 2024

First Use in Commerce

August 19, 2024

Goods & Services

drug discovery services; pharmaceutical research services; pharmaceutical products development; pharmaceutical research and development; pharmaceutical drug development services; consulting services in the field of pharmaceutical research and development; technical consulting in the field of pharmaceutical studies; technical research in the field of pharmaceutical studies; research and development services of new pharmaceutical products; research and development in the pharmaceutical and biotechnology fields; providing medical research information in the field of pharmaceuticals; providing medical and scientific research information in the fields of pharmaceuticals and genetics; Research in the field of bioinformatics; biological and bio-technology analysis services; DNA sequencing technology research; research in the field of DNA mutation; DNA analysis services for scientific research purposes; providing genetic science information; scientific research consulting in the field of pharmaceuticals and drug discovery; medical and scientific research in the field of proteomics; scientific research for medical purposes in the field of proteomics; drug discovery services that utilize structural analysis, hit finding techniques and computational analysis and targets diseases related to highly dynamic proteins; drug discovery services, namely, drug design; drug discovery services, namely, analysis of structure activity relationships; drug discovery services, namely, medical research and development; drug discovery services, namely, DNA encoded library (DEL) screening; drug discovery services, namely, genetic sequencing services; using artificial intelligence (AI) for drug discovery, pharmaceutical research and development, and medical research and development in the fields of pharmaceuticals and genetics; using machine learning for drug discovery, pharmaceutical research and development, and medical research and development in the fields of pharmaceuticals and genetics; drug discovery services targeting diseases related to highly dynamic proteins by utilizing structural analysis, hit finding techniques and computational analysis; drug discovery services for use in developing and prioritizing lead compounds for drug development; drug discovery services in the fields of biochemistry, biophysics, structural biology and chemistry; drug discovery services in the nature of a knowledge based drug discovery platform; drug discovery services in the nature of data analysis software for use in drug discovery; drug discovery services in the nature of drug discovery software utilizing hit finding techniques

chemical and biochemical preparations and substances for medical purposes for treatment and diagnosis of cancer, autoimmune disease, and other diseases that involve the functionality of highly dynamic proteins; immunotherapy products, namely, pharmaceutical preparations for the treatment of cancer, autoimmune diseases, and immunological disorders

Filing History

NOTIFICATION OF FINAL REFUSAL EMAILED
Feb 10, 2026 GNFN
FINAL REFUSAL E-MAILED
Feb 10, 2026 GNFR
FINAL REFUSAL WRITTEN
Feb 10, 2026 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 12, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 12, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 12, 2026 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Oct 3, 2025 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Oct 3, 2025 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 14, 2025 GNRN
NON-FINAL ACTION E-MAILED
Jul 14, 2025 GNRT
NON-FINAL ACTION WRITTEN
Jul 14, 2025 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 10, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 10, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 10, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 11, 2025 GNRN
NON-FINAL ACTION E-MAILED
Mar 11, 2025 GNRT
NON-FINAL ACTION WRITTEN
Mar 11, 2025 CNRT
ASSIGNED TO EXAMINER
Mar 4, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 17, 2025 NWOS
NEW APPLICATION ENTERED
Aug 27, 2024 NWAP